|
WO2020150703A1
|
|
Cgrp antagonists for treating migraine breakthrough
|
|
WO2020077038A1
|
|
Prodrugs of cgrp antagonists
|
|
AU2019277080A1
|
|
Use of riluzole oral disintigrating tablets for treating diseases
|
|
CN112153969A
|
|
Rimazepam for CGRP related disorders
|
|
CA3082096A1
|
|
Use of riluzole prodrugs to treat ataxias
|
|
US2020299238A1
|
|
Prodrugs of lanicemine and their method of use
|
|
WO2018031707A1
|
|
Acyl benzo[d]thiazol-2-amine and their methods of use
|
|
AU2017266951A1
|
|
Use of Glutamate modulating agents with Immunotherapies to treat cancer
|
|
US2018318268A1
|
|
Amine prodrugs of pharmaceutical compounds
|
|
WO2016140878A2
|
|
Prodrugs riluzole and their method of use
|
|
AU2015350142A1
|
|
Sublingual administration of riluzole
|
|
WO2016081472A1
|
|
Sublingual formulation of riluzole
|
|
US2015148329A1
|
|
Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
|
|
US2015045401A1
|
|
Prodrugs of riluzole and their method of use
|
